COM902 is a therapeutic immuno-oncology antibody targeting TIGIT.
COM902 is being developed as an integral component of the COM701 program, to provide the company with an internally-developed antibody to facilitate the combination strategy for COM701 – to test COM701 and COM902 as a dual combination, as well as in triple combination with PD-1 inhibitors. Based on the pathway association of PVRIG with TIGIT, it was explored whether combined inhibition of both PVRIG and TIGIT would lead to increased activation of T cells beyond inhibition of each separately.
Expression studies show that PVRIG and TIGIT, and their respective ligands, are expressed in a broad variety of tumor types, such as breast, endometrial, ovarian, lung, kidney, and head & neck cancers. These results indicate that within the same tumor indications there are variations with respect to the dominance of the two pathways, and that in patient populations where the two pathways are operative, the blockade of both TIGIT and PVRIG may be required to sufficiently stimulate an anti-tumor immune response.
TIGIT was discovered by Compugen utilizing its computational predictive discovery infrastructure and experimentally validated as an immune checkpoint. The findings were published by Compugen in the October 2009 issue of the Proceedings of National Academy of Sciences (PNAS).
The Company intends to initiate Phase 1 studies in patients with advanced malignancies in early 2020 pursuant to the FDA’s clearance of an investigational new drug (IND) application in October 2019.
COM902 is currently being evaluated in a Phase 1 study in patients with advanced malignancies. The study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of escalating doses of COM902 monotherapy.
The Phase 1 study is currently enrolling at leading centers in the United States and is expected to include approximately 45 patients. Additional Information on the COM902 Phase 1 clinical trial can be found here.